Aculon, Inc. v. Electrolab, Inc.

CourtDistrict Court, W.D. Texas
DecidedAugust 21, 2024
Docket5:23-cv-00720
StatusUnknown

This text of Aculon, Inc. v. Electrolab, Inc. (Aculon, Inc. v. Electrolab, Inc.) is published on Counsel Stack Legal Research, covering District Court, W.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Aculon, Inc. v. Electrolab, Inc., (W.D. Tex. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TEXAS SAN ANTONIO DIVISION

ACULON, INC., A CALIFORNIA § CORPORATION; § Plaintiff § SA-23-CV-00720-XR § -vs- § § ELECTROLAB, INC., A TEXAS § CORPORATION; AND E9 § TREATMENTS, INC., A DELAWARE CORPORATION; Defendants

ORDER On this date, the Court considered the parties’ opening claim construction briefs (ECF Nos. 68, 69), the responsive claim construction briefs (ECF Nos. 70, 71), the reply claim construction briefs (ECF Nos. 72, 73), and the parties’ sur-replies (ECF Nos. 74, 75). In addition, the Court considered the arguments made by the parties at the Markman hearing held on June 27, 2024, and the joint claim construction charts (ECF No. 59). After careful consideration, the Court issues the following order construing four disputed claim terms. BACKGROUND On September 2, 2022, Aculon filed suit in the Southern District of California against Defendants Electrolab, Inc. and e9 Treatments, Inc., alleging, among other things, a cause of action for patent infringement solely against e9. According to Aculon, e9 infringed U.S. Patent No. 8,025,974 (the “’974 Patent”) and U.S. Patent No. 8,236,426 (the “’426 Patent”) (collectively, the “Aculon Asserted Patents”). ECF No. 1. On May 31, 2023, the Southern District of California transferred the case to this Court. ECF No. 27. On June 14, 2023, Defendants filed a motion to dismiss, challenging Aculon’s causes of action for “(1) Misappropriation of Trade Secrets; (2) Intentional Interference with Contractual Relations; (3) Intentional Interference with Prospective Economic Advantage; (4) Negligent Interference with Prospective Economic Advantage; and (5) Conversion pursuant to Federal Rules of Civil Procedure 12(b)(6).” ECF No. 32. On September 21, 2023, Aculon filed its first amended complaint, dropping many of its

causes of action but retaining its patent infringement cause of action against e9. On October 5, 2023, e9 filed counterclaims against Aculon asserting infringement of U.S. Patent Nos. 10,059,892 (the “’892 Patent”), 10,150,924 (the “’924 Patent”), 10,934,497 (the “’497 Patent”) (collectively, the “e9 Asserted Patents”). At a high level, the patents at issue relate to the structure and application of self-assembled monolayers (“SAMs”). SAMs are molecules that can bond with clean surfaces to form thin coatings because of their molecular structure. ECF No. 69 at 2. When the head of the SAM molecule includes the element phosphorous, the molecules are referred to as self-assembled monolayers of phosphonate (“SAMPs”). ECF No. 69 at 2. SAMs and SAMPs have a variety of

applications. ECF No. 68 at 4. On February 16, 2024, the parties filed their joint claim construction brief, identifying four claim terms in dispute. ECF No. 59. On March 29, 2024, the parties filed their opening claim construction briefs. ECF Nos. 68, 69. On April 12, 2024, the parties filed their respective responsive claim construction briefs. ECF Nos. 70, 71. On April 19, 2024, the parties filed their replies. ECF Nos. 72, 73. And on April 26, 2024, the parties filed their sur-replies. ECF Nos. 74, 75. On June 27, 2024, the Court held a Markman hearing and heard argument on the disputed terms. DISCUSSION I. Legal Standard Claim construction is a matter of law. Markman v. Westview Instruments, Inc., 517 U.S. 370, 372 (1996). “The purpose of claim construction is to ‘determine the meaning and scope of the patent claims asserted to be infringed.’” O2 Micro Int’l Ltd. v. Beyond Innovation Tech. Co.,

521 F.3d 1351, 1360 (Fed. Cir. 2008) (quoting Markman v. Westview Instruments, Inc., 52 F.3d 967, 976 (Fed. Cir. 1995) (en banc), aff’d 517 U.S. 370 (1996)). “When the parties present a fundamental dispute regarding the scope of a claim term, it is the court’s duty to resolve it.” O2, 521 F.3d at 1362. Claim terms “are generally given their ordinary and customary meaning.” Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed. Cir. 1996). The ordinary and customary meaning of a term “is the meaning that the term would have to a person of ordinary skill in the art in question at the time of invention[.]” Phillips v. AWH Corp., 415 F.3d 1303, 1313 (Fed. Cir. 2005). “In some

cases, the ordinary meaning of claim language as understood by a person of skill in the art may be readily apparent[.]” Id. at 1314. “[C]laim construction in such cases involves little more than the application of the widely accepted meaning of commonly understood words.” Id. Indeed, “[w]hile claim construction is a matter for the Court, it need not provide a new definition or rewrite a term, particularly when the Court finds the term’s plain and ordinary meaning is sufficient.” Alexam, Inc. v. Best Buy Co., No. 2:10CV93, 2012 U.S. Dist. LEXIS 49511, at *18 (E.D. Tex. Apr. 9, 2012). However, “because the meaning of a claim term as understood by persons of skill in the art is often not immediately apparent, . . . the court looks to ‘those sources available to the public

that show what a person of skill in the art would have understood disputed claim language to mean.’” Phillips, 415 F.3d at 1314 (quoting Innova/Pure Water, Inc. v. Safari Water Filtration Sys., Inc., 381 F.3d 1111, 1116 (Fed. Cir. 2004)). “Those sources include ‘the words of the claims themselves, the remainder of the specification, the prosecution history, and extrinsic evidence concerning relevant scientific principles, the meaning of technical terms, and the state of the art.’” Id.

“To properly construe a claim term, a court first considers the intrinsic evidence, starting with the language of the claims.” Merck & Co. v. Teva Pharms. USA, Inc., 395 F.3d 1364, 1369– 70 (Fed. Cir. 2005) (citing Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed.Cir.1996)). “If the meaning of a claim term is clear from the intrinsic evidence, there is no reason to resort to extrinsic evidence.” Seabed Geosolutions (US) Inc. v. Magseis FF LLC, 8 F.4th 1285, 1287 (Fed. Cir. 2021). In turn, courts “resort to extrinsic evidence to construe claims only if it is consistent with the intrinsic evidence.” Id.; see also Phillips, 415 F.3d at 1318. II. Analysis a. Applicable Person of Ordinary Skill in the Art

The parties submit two different persons of ordinary skill in the art for the patents at issue— one for the e9 Asserted Patents and one for the Aculon Asserted Patents. The Court addresses each below. i. Person of Ordinary Skill in the Art for the e9 Asserted Patents First, with respect to the e9 Asserted Patents, Aculon submits that the applicable person of ordinary skill in the art “should be someone with at least a Bachelor of Science in Chemistry.” ECF No. 68 at 7.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Respironics, Inc. v. Invacare, Corp.
303 F. App'x 865 (Federal Circuit, 2008)
Merck & Co. v. Teva Pharmaceuticals USA, Inc.
395 F.3d 1364 (Federal Circuit, 2005)
Aia Engineering Ltd. v. Magotteaux Intern. S/A
657 F.3d 1264 (Federal Circuit, 2011)
Thorner v. Sony Computer Entertainment America LLC
669 F.3d 1362 (Federal Circuit, 2012)
In Re GPAC Inc.
57 F.3d 1573 (Federal Circuit, 1995)
Vitronics Corporation v. Conceptronic, Inc.
90 F.3d 1576 (Federal Circuit, 1996)
Chef America, Inc. v. Lamb-Weston, Inc.
358 F.3d 1371 (Federal Circuit, 2004)
Home Diagnostics, Inc. v. Lifescan, Inc.
381 F.3d 1352 (Federal Circuit, 2004)
E.digital Corporation v. Futurewei Technologies, Inc.
772 F.3d 723 (Federal Circuit, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
Aculon, Inc. v. Electrolab, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/aculon-inc-v-electrolab-inc-txwd-2024.